304 related articles for article (PubMed ID: 28410143)
1. Targeted radionuclide therapy: frontiers in theranostics.
Gallivanone F; Valente M; Savi A; Canevari C; Castiglioni I
Front Biosci (Landmark Ed); 2017 Jun; 22(10):1750-1759. PubMed ID: 28410143
[TBL] [Abstract][Full Text] [Related]
2. Theranostic Advances in Breast Cancer in Nuclear Medicine.
Vahidfar N; Aghanejad A; Ahmadzadehfar H; Farzanehfar S; Eppard E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925632
[TBL] [Abstract][Full Text] [Related]
3. Nuclear medicine theranostics comes of age.
Herrmann K; Kraus BJ; Hadaschik B; Kunikowska J; van Poppel H; N'Dow J; Sartor O; Oyen WJG
Lancet Oncol; 2021 Nov; 22(11):1497-1498. PubMed ID: 34735807
[No Abstract] [Full Text] [Related]
4.
Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
[TBL] [Abstract][Full Text] [Related]
5. Radioligand Theranostics in the Management of Neuroendocrine Tumors.
Harris AG; Vinik AI; OʼDorisio TM; OʼDorisio MS
Pancreas; 2020; 49(5):599-603. PubMed ID: 32433395
[No Abstract] [Full Text] [Related]
6. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract][Full Text] [Related]
7. Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More.
Turner JH
Cancer Biother Radiopharm; 2019 Apr; 34(3):135-140. PubMed ID: 30973278
[No Abstract] [Full Text] [Related]
8. Theranostic approaches in nuclear medicine: current status and future prospects.
Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
[No Abstract] [Full Text] [Related]
9. Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.
Miller C; Rousseau J; Ramogida CF; Celler A; Rahmim A; Uribe CF
Theranostics; 2022; 12(1):232-259. PubMed ID: 34987643
[TBL] [Abstract][Full Text] [Related]
10. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.
Gomes Marin JF; Nunes RF; Coutinho AM; Zaniboni EC; Costa LB; Barbosa FG; Queiroz MA; Cerri GG; Buchpiguel CA
Radiographics; 2020 Oct; 40(6):1715-1740. PubMed ID: 33001789
[TBL] [Abstract][Full Text] [Related]
11. Alpha emitting nuclides in nuclear medicine theranostics.
Miederer M
Nuklearmedizin; 2022 Jun; 61(3):273-279. PubMed ID: 34624903
[TBL] [Abstract][Full Text] [Related]
12. Nuclear imaging in cancer theranostics.
Del Vecchio S; Zannetti A; Fonti R; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2007 Jun; 51(2):152-63. PubMed ID: 17420716
[TBL] [Abstract][Full Text] [Related]
13. Toward Independent Nuclear Medicine, Molecular Imaging, and Theranostic Programs.
Czernin J
J Nucl Med; 2019 Aug; 60(8):1037. PubMed ID: 31371618
[No Abstract] [Full Text] [Related]
14. Targeted radionuclide therapy directed to the tumor phenotypes: A dosimetric approach using MC simulations.
Borbinha J; Ferreira P; Costa D; Vaz P; Di Maria S
Appl Radiat Isot; 2023 Feb; 192():110569. PubMed ID: 36436229
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric effectiveness of targeted radionuclide therapy based on a pharmacokinetic landscape.
Grudzinski JJ; Burnette RR; Weichert JP; Jeraj R
Cancer Biother Radiopharm; 2010 Aug; 25(4):417-26. PubMed ID: 20735205
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review.
Li T; Ao ECI; Lambert B; Brans B; Vandenberghe S; Mok GSP
Theranostics; 2017; 7(18):4551-4565. PubMed ID: 29158844
[TBL] [Abstract][Full Text] [Related]
17. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.
Duan H; Iagaru A; Aparici CM
Nanotheranostics; 2022; 6(1):103-117. PubMed ID: 34976584
[TBL] [Abstract][Full Text] [Related]
18. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.
Bolcaen J; Kleynhans J; Nair S; Verhoeven J; Goethals I; Sathekge M; Vandevoorde C; Ebenhan T
Theranostics; 2021; 11(16):7911-7947. PubMed ID: 34335972
[TBL] [Abstract][Full Text] [Related]
19. Brain metastasis: An insight into novel molecular targets for theranostic approaches.
Santos L; Moreira JN; Abrunhosa A; Gomes C
Crit Rev Oncol Hematol; 2024 Jun; 198():104377. PubMed ID: 38710296
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.
D'Huyvetter M; Xavier C; Caveliers V; Lahoutte T; Muyldermans S; Devoogdt N
Expert Opin Drug Deliv; 2014 Dec; 11(12):1939-54. PubMed ID: 25035968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
